Phathom Pharmaceuticals, Inc. (PHAT)

10.89 +0.35 (+3.32%) 收市：04:00PM EDT

Phathom Pharmaceuticals, Inc.

100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
https://www.phathompharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 452

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Terrie J. Curran	President, CEO & Director	1.22M	無	1969
Mr. David A. Socks	Co-Founder & Director	54.17k	無	1975
Dr. Azmi Nabulsi M.D., M.P.H.	Co-Founder & COO	888.9k	無	1960
Ms. Molly Henderson CPA, MBA	Chief Financial & Business Officer	777.76k	無	1971
Dr. Aditya Kohli Ph.D.	Co-Founder	319.65k	無	1988
Mr. Paul Cocja	Chief People Officer	無	無	無
Mr. Tom Harris	Chief Development Sciences Officer	無	無	無
Dr. Eckhard Leifke M.D., Ph.D.	Chief Medical Officer	無	無	無
Mr. Martin J. Gilligan	Chief Commercial Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

公司管治

截至 2024年5月1日 止，Phathom Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：6；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。